{"name":"Mallinckrodt Pharmaceuticals","slug":"mallinckrodt","ticker":"MNK","exchange":"NYSE","domain":"mallinckrodt.com","description":"Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals, generic drugs and imaging agents.\nIn 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system.","hq":"Staines-upon-Thames, UK (operational HQ: Hampton, NJ)","founded":0,"employees":"","ceo":"Sigurdur Olafsson","sector":"Specialty Pharma / Generics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$750M","metrics":{"revenue":1750000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1959-01-01","label":"Phosphotope first approved","drug":"Phosphotope","drugSlug":"sodium-phosphate-32p","type":"approval","sentiment":"positive"},{"date":"1968-01-01","label":"Cyanocobalamin Co 57 first approved","drug":"Cyanocobalamin Co 57","drugSlug":"cyanocobalamin-57co","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-01","label":"Oxycodone hydrochloride tablet 15 mg patent cliff ($1.4B at risk)","drug":"Oxycodone hydrochloride tablet 15 mg","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"IV Acetaminophen patent cliff ($1.1B at risk)","drug":"IV Acetaminophen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"cardiovascular","drugs":[{"name":"Gelatin sponge","genericName":"Gelatin sponge","slug":"gelatin-sponge","indication":"Hemostasis in surgical procedures","status":"phase_3"},{"name":"IV Control","genericName":"IV Control","slug":"iv-control","indication":"Control of intravenous medication administration","status":"phase_3"},{"name":"Actiq 400 mcg","genericName":"Actiq 400 mcg","slug":"actiq-400-mcg","indication":"Other","status":"phase_1"},{"name":"Cholebrine","genericName":"IOCETAMIC ACID","slug":"iocetamic-acid","indication":"Other","status":"marketed"},{"name":"Fibrocaps","genericName":"Fibrocaps","slug":"fibrocaps","indication":"Other","status":"phase_3"},{"name":"Oxycodone hydrochloride tablet 15 mg","genericName":"Oxycodone hydrochloride tablet 15 mg","slug":"oxycodone-hydrochloride-tablet-15-mg","indication":"Other","status":"marketed"},{"name":"Phosphotope","genericName":"sodium phosphate (32P)","slug":"sodium-phosphate-32p","indication":"Polycythemia vera","status":"marketed"},{"name":"Raplixa","genericName":"Raplixa","slug":"raplixa","indication":"Other","status":"discontinued"},{"name":"Repository Corticotropin Injection","genericName":"Repository Corticotropin Injection","slug":"repository-corticotropin-injection","indication":"Other","status":"marketed"},{"name":"Restoril","genericName":"temazepam","slug":"temazepam","indication":"Short-term treatment of insomnia","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"COV795","genericName":"COV795","slug":"cov795","indication":"Autoimmune or inflammatory conditions (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"PENNSAID Gel","genericName":"PENNSAID Gel","slug":"pennsaid-gel","indication":"Osteoarthritis pain of the knee","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Cyanocobalamin Co 57","genericName":"cyanocobalamin (57Co)","slug":"cyanocobalamin-57co","indication":"Cobalamin deficiency","status":"marketed"},{"name":"IK-3001","genericName":"IK-3001","slug":"ik-3001","indication":"Iron deficiency anemia in patients with chronic kidney disease","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"IV Acetaminophen","genericName":"IV Acetaminophen","slug":"iv-acetaminophen","indication":"Management of mild to moderate pain","status":"marketed"},{"name":"IV Acetaminophen (Treatment A)","genericName":"IV Acetaminophen (Treatment A)","slug":"iv-acetaminophen-treatment-a","indication":"Management of mild to moderate pain","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Xe 133","genericName":"xenon (133Xe) gas","slug":"xenon-133xe-gas","indication":"Pulmonary Function Evaluation","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"COV155","genericName":"COV155","slug":"cov155","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Nitric Oxide plus Oxygen","genericName":"Nitric Oxide plus Oxygen","slug":"nitric-oxide-plus-oxygen","indication":"Acute respiratory distress syndrome (ARDS)","status":"phase_3"}]}],"pipeline":[{"name":"Xe 133","genericName":"xenon (133Xe) gas","slug":"xenon-133xe-gas","phase":"marketed","mechanism":"","indications":["Pulmonary Function Evaluation","Lung Imaging","Cerebral Blood Flow Assessment"],"catalyst":""},{"name":"COV795","genericName":"COV795","slug":"cov795","phase":"phase_3","mechanism":"COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Autoimmune or inflammatory conditions (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"Gelatin sponge","genericName":"Gelatin sponge","slug":"gelatin-sponge","phase":"phase_3","mechanism":"Gelatin sponge is a hemostatic agent that absorbs blood and promotes clotting through physical absorption and platelet aggregation.","indications":["Hemostasis in surgical procedures","Control of capillary, venous, and small arterial bleeding"],"catalyst":""},{"name":"IV Control","genericName":"IV Control","slug":"iv-control","phase":"phase_3","mechanism":"IV Control is used to control the rate of intravenous medication administration.","indications":["Control of intravenous medication administration"],"catalyst":""},{"name":"Actiq 400 mcg","genericName":"Actiq 400 mcg","slug":"actiq-400-mcg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"COV155","genericName":"COV155","slug":"cov155","phase":"phase_3","mechanism":"COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"Cholebrine","genericName":"IOCETAMIC ACID","slug":"iocetamic-acid","phase":"marketed","mechanism":"Cholebrine works by binding to a specific target, although its exact mechanism of action is currently unknown.","indications":[],"catalyst":""},{"name":"Cyanocobalamin Co 57","genericName":"cyanocobalamin (57Co)","slug":"cyanocobalamin-57co","phase":"marketed","mechanism":"Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial, Methionine synthase, Methionine synthase reductase","indications":["Cobalamin deficiency","Iron deficiency anemia","Megaloblastic anemia due to folate deficiency","Pernicious anemia","Prevention of Vitamin B12 Deficiency"],"catalyst":""},{"name":"Fibrocaps","genericName":"Fibrocaps","slug":"fibrocaps","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IK-3001","genericName":"IK-3001","slug":"ik-3001","phase":"phase_3","mechanism":"IK-3001 is an intravenous iron replacement therapy that replenishes depleted iron stores in patients with iron deficiency.","indications":["Iron deficiency anemia in patients with chronic kidney disease","Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron"],"catalyst":""},{"name":"IV Acetaminophen","genericName":"IV Acetaminophen","slug":"iv-acetaminophen","phase":"marketed","mechanism":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.","indications":["Management of mild to moderate pain","Management of moderate to severe pain with opioids","Fever reduction"],"catalyst":""},{"name":"IV Acetaminophen (Treatment A)","genericName":"IV Acetaminophen (Treatment A)","slug":"iv-acetaminophen-treatment-a","phase":"marketed","mechanism":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.","indications":["Management of mild to moderate pain","Reduction of fever","Management of moderate pain with opioids"],"catalyst":""},{"name":"Nitric Oxide plus Oxygen","genericName":"Nitric Oxide plus Oxygen","slug":"nitric-oxide-plus-oxygen","phase":"phase_3","mechanism":"Nitric oxide gas combined with oxygen improves oxygenation and vasodilation in the lungs to reduce pulmonary hypertension and improve gas exchange.","indications":["Acute respiratory distress syndrome (ARDS)","Pulmonary hypertension in critically ill patients","Hypoxemic respiratory failure"],"catalyst":""},{"name":"Oxycodone hydrochloride tablet 15 mg","genericName":"Oxycodone hydrochloride tablet 15 mg","slug":"oxycodone-hydrochloride-tablet-15-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PENNSAID Gel","genericName":"PENNSAID Gel","slug":"pennsaid-gel","phase":"phase_3","mechanism":"PENNSAID is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation at the site of application.","indications":["Osteoarthritis pain of the knee","Osteoarthritis pain of other joints"],"catalyst":""},{"name":"Phosphotope","genericName":"sodium phosphate (32P)","slug":"sodium-phosphate-32p","phase":"marketed","mechanism":"","indications":["Polycythemia vera"],"catalyst":""},{"name":"Raplixa","genericName":"Raplixa","slug":"raplixa","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Repository Corticotropin Injection","genericName":"Repository Corticotropin Injection","slug":"repository-corticotropin-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Restoril","genericName":"temazepam","slug":"temazepam","phase":"marketed","mechanism":"Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","indications":["Short-term treatment of insomnia"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Mallinckrodt Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Mallinckrodt Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with net sales of $1.4 billion for the full year.","drugName":"","sentiment":"neutral"},{"date":"2023-05-01","type":"deal","headline":"Mallinckrodt Pharmaceuticals Announces Agreement to Sell Its Specialty Generics Business to Teva Pharmaceutical Industries","summary":"Mallinckrodt Pharmaceuticals announced an agreement to sell its specialty generics business to Teva Pharmaceutical Industries.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"regulatory","headline":"FDA Approves Mallinckrodt Pharmaceuticals' Repository Corticotropin Injection","summary":"The FDA approved Mallinckrodt Pharmaceuticals' Repository Corticotropin Injection for the treatment of infantile spasms.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQZVJCS1czNEVXanZlcmY3SXlkYTl4S2xaSlpmUmlPVFNJUXBjTWFzc3RYb1FiMG9rcDlCcDRnQXFtTG1EOTVqZEcwdmJjN25OQUQ3N1NWUjRzaERaQVdKVXFwTmNvdmxuTVE1UHBEajVBMjI3czdhY2xWS3RGa1kydDkxbnpETC1oWlRYa0paRTdBeFhIT19zZ1ZtcjhYakpZN2g3WGR6N0NqR2xlN2xHUkk5Mkh1MjBPLWtsTmlSZjFJN1ZadGxrSHliTldtUQ?oc=5","date":"2025-09-22","type":"pipeline","source":"PR Newswire","summary":"Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer - PR Newswire","headline":"Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQbFdaemhrMmlyUXNmMzY3QkhSU0NjWE80TmRMckhHVWtwZ3RGQ2pzVTBETGZITmdFRUtRdkgyeFpSanlSanZUcXNvLXJHOURzV1ZLNzhSeVFpQU5tbHV0blI5LUh1NERTV1o5cEpSRTZQYTljT3UzZXpEZEprV2g4bTJxb2NrWVA5QWhKRTdVTmlRblNRUkpTcWdKQW5mYlkyR1lqOXJxVF8tMVY1YU1hU3FwY3g0bTJheS1RRkRlNVRHRGJmcnFrVU1Cd0RxaVFORjFmNW03eU51SGpmZHc?oc=5","date":"2025-08-01","type":"deal","source":"PR Newswire","summary":"Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader - PR Newswire","headline":"Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPQUZxU29yMG13cVQyQnB2ZXZKVXd5a2J5WlBjNHM4WE03NnFjb3RzanJmT2htZ1A0bDdRcVZ6Z181R3l6ZUk0ME00OHFhUm1FU056dE1oTDl0N1BBWC1RSTBEYnhJazZRamd1OVkyakx4cDU0OEZOeFAzYUUzaVhtSFQ1aXBBUGhRNEdxay1MXzJlczlUeGY3UkZaUlBmRnBEaWhIM2NsckNBb0ljSGdQTHl2X21OR3Z3MVVfanBVSzVKdWJJQXBxRk56aVN4MUNqLWZueDZHaGk5V0c2cnc0RnhZWm9jb3JOV3dORTJqWVFVZmd2WDFBLXBNSWRBd3Qx?oc=5","date":"2025-06-13","type":"regulatory","source":"PR Newswire","summary":"Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader - PR Newswire","headline":"Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOaFUtYXNpcWtpVlVScUhMdHBvOWVDZGNJU2lOYV8yUVM1Q1c2XzdmOHRreVBjRmNqTXZzWmdrRkZITXR3TlY0VEVfN2s1TFJzbWljTUgwODdjYm54N2RMUm5pdUVqSjZrVS0xS1pYSkE3aW5WT29qTFBURmRCejJ5ZjZQQjTSAYoBQVVfeXFMT0xXTjNMdWZpUmdlUldwZDRJQmdaVHZIRWkyS3duWDRvVDg5c1ludTRSRUpvdTB1UDZHbjM3Z1ZEMVd0c2NSWnQtWmI1OXZpTWdTQVlVS202LXh5clZlVFZjUlJ2S2h3MERUTkdTTXF4TjdXYm80UHQtUnhYcEMtYTFWT3Y0QVQ5ZHln?oc=5","date":"2025-03-13","type":"deal","source":"CNBC","summary":"Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal - CNBC","headline":"Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQZkcwdVVfTExqc1dEWVI1XzdYd3BmMUtucmhGMnY4dGJyOVMtNkJEWmJLN00tek1qckRIc2FsWDNJR0czWEtucHFHbEtFUFVkS1phZUlnbE44ZlB6RF9hTURWakpzZTVmSHlpTmltYXdhOThpa1N4TEJDQ21EQ1lmMzR3aWdTLVltU1Z3M3lLcHBHQ2pkOVZfUHprQTdzeWs4Y2N6SkdB?oc=5","date":"2025-03-13","type":"deal","source":"Fierce Pharma","summary":"Mallinckrodt, Endo look to carve out brighter future through $6.7B merger - Fierce Pharma","headline":"Mallinckrodt, Endo look to carve out brighter future through $6.7B merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPOF9UUTJUS1RjNEZxOG50X2t0Y2ZydXIzcmVmZDZLdEVjUGg4cUxuaXRqOHNkRUxYY29OUHJJWDV5VWlEVWpVeVMwMElkRkhNOU84bnYzekdnMnBQaUl3dWFaMlFqelJKQTZCOVh6T1IxNzRHODJzb0dvbUdOcjZSQlYteFNSMGdqWW5TMll1ejRfM0VEV2RCbmg1eE41NGlhOHJITnF4N3FNbmlESnc?oc=5","date":"2025-03-13","type":"deal","source":"Bloomberg.com","summary":"Mallinckrodt Pharma, Endo Reach Deal for $6.7 Billion Merger - Bloomberg.com","headline":"Mallinckrodt Pharma, Endo Reach Deal for $6.7 Billion Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPREhZajlsSlBjM29EU1pyNEZ0bUlVbldSLXF5akJoSmt2dmRTZlpxa1FXWk1IUWhkd0JmblJmazdqS2FHWEs3N0VFbWoxNXpBSXQ0aE1tR3Vwd1ItVnB4d1o2a291S3RMbmZSOGpqQzlXOHl3bVliRy1Cd2RKT2VlcWhOdjM4QkVHOE9VVmZXRzNpdTBtUFdvU3FoYS1yU3g1aXRlZGp0bm5FX3VxMERaUmVvSmRockk4eHZRLTVn?oc=5","date":"2023-08-28","type":"pipeline","source":"reuters.com","summary":"Drugmaker Mallinckrodt files for second bankruptcy in US - reuters.com","headline":"Drugmaker Mallinckrodt files for second bankruptcy in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8yUkhrQWpWVVA5bmpjaWUwUl9BREFLS1llRXBJanhhM0k5d2lfTmpURjU4OXZ1em9HNWxDSnNaclV4aGYtRG1XXzRVTGE3c3AwaDJR?oc=5","date":"2018-12-21","type":"trial","source":"firstwordpharma.com","summary":"Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy - firstwordpharma.com","headline":"Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQSkFlazdwbkR6M0M0NVZ0N2FfNGRRaWhnMllVbVFveDFmeXZFRXBlcGl4UUJPc0lZRU04NFhOUkFPbW9nVWdNQkNYRm0xdWJuT0M3SDZhOEYycWJEZmN5ZTk2OEVSdUlRZlNWRV8wV0IwRjdOR0NPa3JBVElrcklwR1JpdkgtR0RhQ0N3TG52LUpTSjVvWFRMNWZlZno5WndTOEVYZEs3MDZGZnRSNzZxdGlDUS1iTnAzRnVjekhzdUM0X0Iy?oc=5","date":"2018-12-06","type":"patent","source":"Fierce Pharma","summary":"Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image - Fierce Pharma","headline":"Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNemhhd1hwZGxmcDBaQTBJRXB0MUE4aDFZOUx3aktsZnZ3V3lYY1JLM0cyekhRaGhmVXM1dTh3ZHJfLUxmTjhHY2gwZzNpMm94UDZHSHFyNXlKb2UtZUVfVmYtelJ4RUZ0dmRoV0pwY3g2X3lieGFkQ0I4Qkk2M1FUWHVkM05veGNHazl5bUkzSkxiNFdUM3c2YUpyb3c0SzRhYWZ1LVNFeF8xMFJCbEl1R2Z4WEhVVmVfamc3emFZMG5UR1dsYkE?oc=5","date":"2017-02-08","type":"pipeline","source":"Fierce Pharma","summary":"Mallinckrodt highlights patient success stories to spruce up its image—and the industry’s - Fierce Pharma","headline":"Mallinckrodt highlights patient success stories to spruce up its image—and the industry’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQNnZFbFVJenBodlc1YjRvczVoeVBXNWdQRXRQWFRrWkhnTTFRUVplei1ZN0NCaTlyZ18zaVdPdldrSjA2UU9kb01fMnpUNmtzYm05UlMtZF8wNXpmaGRJQ1BwaDhzLXhBcW5oUjU2Qk5nM191YUhiZUhWOG1EcDF0X09ia1JKUUl2UXc?oc=5","date":"2016-12-23","type":"deal","source":"Drug Delivery Business","summary":"Mesoblast gains on A$29m investment deal with Mallinckrodt - Drug Delivery Business","headline":"Mesoblast gains on A$29m investment deal with Mallinckrodt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNUGJEd3hON3JxNHNGYzc3RjkzMEZQZTctWHZDQzYxTTF6dmc0cXZWM19GclN0N1NSejlJVUMwd2hFUExKM1dVRWNRV01sNjVZNXQxam12Y1czR1psQlMzWUNnV3NwbnBLTUF4WFhhN3FXeFA2NjJxNVpITENpUnI5SDJmNGloQTdIRUQ2RVdzdkxhUmNIc0ZEaXgzMEpBMmEtOHRuMA?oc=5","date":"2014-05-29","type":"regulatory","source":"BioPharma Dive","summary":"FDA accepts NDA from Mallinckrodt for combo pain medication - BioPharma Dive","headline":"FDA accepts NDA from Mallinckrodt for combo pain medication","sentiment":"neutral"}],"patents":[{"drugName":"Oxycodone hydrochloride tablet 15 mg","drugSlug":"oxycodone-hydrochloride","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"IV Acetaminophen","drugSlug":"acetaminophen","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":19,"phaseCounts":{"marketed":9,"phase_3":8,"phase_1":1,"discontinued":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Teva Pharmaceutical Industries","Endo International","Purdue Pharma"],"therapeuticFocus":["Pain Management","Hospital Acute Care","Autoimmune Diseases"],"financials":null,"yahoo":null}